Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literature.

Ingegnoli F, Favalli EG, Meroni PL.

Autoimmun Rev. 2011 Jun;10(8):460-3. doi: 10.1016/j.autrev.2011.01.010. Epub 2011 Feb 4. Review.

PMID:
21296193
2.

An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents.

Ranganathan P.

Curr Opin Mol Ther. 2008 Dec;10(6):562-7. Review.

PMID:
19051134
3.

Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis.

Pavy S, Toonen EJ, Miceli-Richard C, Barrera P, van Riel PL, Criswell LA, Mariette X, Coenen MJ.

Ann Rheum Dis. 2010 Jun;69(6):1022-8. doi: 10.1136/ard.2009.117622. Epub 2009 Dec 4. Review.

PMID:
19966089
4.

Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register.

Rheumatology (Oxford). 2006 Dec;45(12):1558-65. Epub 2006 May 16.

PMID:
16705046
5.

Genetic and genomic predictors of anti-TNF response.

Prajapati R, Plant D, Barton A.

Pharmacogenomics. 2011 Nov;12(11):1571-85. doi: 10.2217/pgs.11.114. Review.

PMID:
22044414
6.

Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis.

Choy E.

Cytokine. 2004 Nov 21-Dec 7;28(4-5):158-61. Review.

PMID:
15588689
7.

Anti-TNF treatment in rheumatoid arthritis.

Geiler J, Buch M, McDermott MF.

Curr Pharm Des. 2011;17(29):3141-54. Review.

PMID:
21864263
8.

[Current aspects of cost effectiveness of TNF-alpha blocking agents in patients with rheumatoid arthritis].

Merkesdal S, Ruof J.

Z Rheumatol. 2002;61 Suppl 2:II/29-32. Review. German.

PMID:
12491120
9.

Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis.

Ranganathan P.

Pharmacogenomics. 2005 Jul;6(5):481-90. Review.

PMID:
16013998
10.

Biological response modifiers in the management of rheumatoid arthritis.

Louie SG, Park B, Yoon H.

Am J Health Syst Pharm. 2003 Feb 15;60(4):346-55. Review. Erratum in: Am J Health Syst Pharm.2003 Jun 1;60(11):1095.

PMID:
12625216
11.

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium.

Wijbrandts CA, Dijkgraaf MG, Kraan MC, Vinkenoog M, Smeets TJ, Dinant H, Vos K, Lems WF, Wolbink GJ, Sijpkens D, Dijkmans BA, Tak PP.

Ann Rheum Dis. 2008 Aug;67(8):1139-44. Epub 2007 Nov 29.

12.

[Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFalpha agents failed are associated with response to rituximab in rheumatoid arthritis].

Quartuccio L, Salvin S, Saracco M, Lombardi S, Fabris M, Mansutti E, Maset M, Pellerito S, De Vita S.

Reumatismo. 2009 Jul-Sep;61(3):182-6. Italian.

13.

Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept.

Koczan D, Drynda S, Hecker M, Drynda A, Guthke R, Kekow J, Thiesen HJ.

Arthritis Res Ther. 2008;10(3):R50. doi: 10.1186/ar2419. Epub 2008 May 2.

14.

Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions.

Plenge RM, Criswell LA.

Curr Opin Rheumatol. 2008 Mar;20(2):145-52. doi: 10.1097/BOR.0b013e3282f5135b. Review.

PMID:
18349743
15.

Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.

Barrera P, van der Maas A, van Ede AE, Kiemeney BA, Laan RF, van de Putte LB, van Riel PL.

Rheumatology (Oxford). 2002 Apr;41(4):430-9.

PMID:
11961174
16.

Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.

Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, Wilson AG, Binks MH, Dickson MC.

Arthritis Rheum. 2008 Aug;58(8):2257-67. doi: 10.1002/art.23667.

17.

The therapeutic potential of TNF-alpha blockade in rheumatoid arthritis.

Paleolog E.

Expert Opin Investig Drugs. 2003 Jul;12(7):1087-95. Review.

PMID:
12831345
18.

[Proposal for anti-TNFalpha therapy in adult patients with rheumatoid arthritis].

Curković B, Babić-Naglić D, Morović-Vergles J, Anić B, Grazio S.

Reumatizam. 2007;54(1):16-9. Review. Croatian. Erratum in: Reumatizam. 2009;56(1):58.

PMID:
18450272
19.

[Clinical experience with TNF-blockers].

Forster A, Michel BA.

Z Rheumatol. 2001 Oct;60(5):319-25. Review. German.

PMID:
11759231
20.

Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors.

Mewar D, Wilson AG.

Br J Pharmacol. 2011 Feb;162(4):785-91. doi: 10.1111/j.1476-5381.2010.01099.x. Review.

Supplemental Content

Support Center